November 24, 2016 - By Clifton Ray · 0 Comments
The stock of ACTELION LTD (OTCMKTS:ALIOF) registered an increase of 36.73% in short interest. ALIOF’s total short interest was 124,700 shares in November as published by FINRA. Its up 36.73% from 91,200 shares, reported previously. With 700 shares average volume, it will take short sellers 178 days to cover their ALIOF’s short positions. The stock decreased 2.07% or $3.24 on November 23, hitting $153.55. About 398 shares traded hands. Actelion Ltd (OTCMKTS:ALIOF) has declined 5.44% since April 22, 2016 and is downtrending. It has underperformed by 10.85% the S&P500.
Actelion Ltd is a Switzerland-based biopharmaceutical firm that focuses on the discovery, development and commercialization of drugs for diseases with unmet medical needs. The company has a market cap of $16.90 billion. The Firm specializes in the field of pulmonary arterial hypertension , a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs. It currently has negative earnings. The Company’s portfolio of PAH treatments includes Opsumit (macitentan), Tracleer (bosentan), Uptravi (selexipag), Veletri (epoprostenol for injection) and Ventavis (iloprost).
More notable recent Actelion Ltd (OTCMKTS:ALIOF) news were published by: Bloomberg.com which released: “Actelion Using Combination Strategy to Attack Multiple Sclerosis” on October 20, 2016, also Seekingalpha.com with their article: “Actelion Re-Awakens Research On Sleep Medicine” published on July 08, 2016, Wsj.com published: “Actelion First-Quarter Earnings Gain 25%; Raises Full-Year Guidance” on April 21, 2015. More interesting news about Actelion Ltd (OTCMKTS:ALIOF) were released by: Law360.com and their article: “Actelion Settles Row Over Giving Drugs To Generics Makers” published on March 01, 2014 as well as Bloomberg.com‘s news article titled: “Actelion Surges on Report of $18.9 Billion Shire Approach” with publication date: June 08, 2015.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Clifton Ray